Study explorer (study characteristics and results) method abbreviations pdf   xlsx

display ongoing studies
Study Ref. Design studied treatmentcontrol treatmentpatientsstudy risk of biassample sizes Results

COVID 19 hospitalized meta-analysis

Li
  ChiCTR2000029638		 RCTrecombinant super-compound interferon rSIFN-coIFN alphaCOVID 19 hospitalizedsome concern
48/48 conclusif
  • demonstrated 76 % increase in clinical improvement,clinical improvement (time to event analysis only) (PE) with a moderate degree of certainty due to some concern in risk of bias
  • suggested 1.9-fold increase in clinical improvement (14-day) with a moderate degree of certainty due to some concern in risk of bias
  • suggested 3.3-fold increase in clinical improvement (28-day) with a moderate degree of certainty due to some concern in risk of bias
  • suggested 74 % increase in viral clearance (time to event analysis only) with a moderate degree of certainty due to some concern in risk of bias
Synairgen SG016
  NCT04385095		 RCTSNG001 inhaled interferon betaplaceboCOVID 19 hospitalizedsome concern
50/51 suggested
  • suggested 1.3-fold increase in clinical improvement with a moderate degree of certainty due to some concern in risk of bias
  • suggested 2.2-fold increase in clinical improvement (28-day) with a moderate degree of certainty due to some concern in risk of bias
1 study excluded by filtering options (1 RCT / 0 OBS)

PE: primary endpoint; (a): to be demonstrated a result must be statistically significant on a primary endpoint (with multiplicity adjustment if necessary);
Study risk of bias assessed for the study primary endpoint(s) or the main endpoints in case of no formally defined primary endpoint(s).

 

- About us - Contact us - Method - RSS Made with in Lyon - Credits - Privacy policy - Licence Creative Commons